Tuberculosis

Short-Course Rifampin and Pyrazinamide Is Effective For Prison Inmates

Published in Medical Letter on the CDC and FDA, April 1st, 2001

A short-course of rifampin and pyrazinamide treatment for tuberculosis was well tolerated and increased the number of jail inmates completing therapy, researchers at the U.S. Centers for Disease Control and Prevention report.

Jail inmates, who constitute a known reservoir of latent tuberculosis infection, could benefit from treatment but are often released before they can complete the traditional six-month isoniazid regimen, N.N. Bock and associates said. The researchers tested a two-month short-course of rifampin and pyrazinamide (2RZ) and found that about half of the inmates that started treatment were able to complete the regimen.

Their...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2001-04-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry